p53 Expression in Correlation to Clinical Outcome in Patients with Renal Cell Carcinoma

References

• Skinner DG, Colvin RB, Vermilion CD, Pfister RC, Leadbetter WE Diagnosis and management of renal cell carcinoma. A clinical and pathological study of 309 cases. Cancer 1971; 28: 1165–77.
   Google Scholar
• Larsson P, Roos G, Stenling R, Ljungberg B. Tumor cell proliferation and prognosis in renal cell carcinoma. Int J Cancer 1993; 55: 566–70.
   PubMed Web of Science ®Google Scholar
• Cross SM, Sanches CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, et al. A p53-dependent mouse spindle checkpoint. Science 1995; 267: 1353–6.
   PubMed Web of Science ®Google Scholar
• Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 435–56.
   Google Scholar
• Quinlan DC, Davidson AG, Summers CL, Warden He, Doshi HM. Accumulation of p53 protein correlates with poor prognosis in human lung cancer. Cancer Res 1992; 52: 4828–31.
   Google Scholar
• Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Canc Inst 1993; 85: 200–6.
   PubMed Web of Science ®Google Scholar
• Moul JW. Angiogenesis, p53, bc1-2 and Ki-67 in the progression of prostate cancer after radical prostatect-omy. Eur Urol 1999; 35: 399–407.
   PubMed Web of Science ®Google Scholar
• Kamel D, Turpeenniemi-Hujanen T, Vahakangas K, Paakko P, Soini Y. Proliferating cell nuclear antigen but not p53 or human papillomavirus DNA correlates with advanced clinical stage in renal cell carcinoma. Histo-pathology 1994; 25: 339–47.
   Google Scholar
• Moch H, Sauter G, Gasser TC, Buchholz N, Bubendorf L, Richter J, et al. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma. Urol Res 1997; 25 (Suppl 1): 25–30.
   PubMedGoogle Scholar
• Sobin LH, Wittekind Ch, editors International Union Against Cancer (UICC). TNM classification of malig-nant tumors. 5th ed. New York: Wiley-Liss; 1997: 180–2.
   Google Scholar
• Ljungberg B, Mehle C, Stenling R, Roos G. Hetero-geneity in renal cell carcinoma and its impact on prognosis-a flow cytometric study. Br J Cancer 1996; 74: 123–7.
   PubMed Web of Science ®Google Scholar
• Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, et al. The Heidelberg classification of renal cell tumors. J Pathol 1997; 183: 131–3.
   PubMed Web of Science ®Google Scholar
• Tannapfel A, Hahn HA, Katalinic A, Fietkau RJ, Kuhn R, Wittekind CW. Incidence of apoptosis, cell prolifera-tion and P53 expression in renal cell carcinomas. Anticancer Res 1997; 17: 1155–62.
   PubMed Web of Science ®Google Scholar
• Uhlman DL, Nguyen PL, Manivel JC, Aeppli D, Resnick JM, Fraley EE, et al. Association of immunohistochem-ical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 1994; 86: 1470–5.
   PubMedGoogle Scholar
• Bot FJ, Godschalk JC, Krishnadath KK, van der Kwast TH, Bosman FT. Prognostic factors in renal-cell carcinoma: immunohistochemical detection of p53 protein versus clinico-pathological parameters. Int J Cancer 1994; 57: 634–7.
   Google Scholar
• Sejima T, Miyagawa I. Expression of bc1-2, p53 oncoprotein, and proliferating cell nuclear antigen in renal cell carcinoma. Eur Urol 1999; 35: 242–8.
   PubMed Web of Science ®Google Scholar
• Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855–78.
   PubMed Web of Science ®Google Scholar
• Kuczyk MA, Serth J, Bokemeyer C, Jonassen J, Arndt H, Paeslack U, et al. Detection of p53 gene alteration in renal-cell cancer by micropreparation techniques of tumor specimens. Int J Cancer 1995; 64: 399–406.
   PubMed Web of Science ®Google Scholar
• Zhang XH, Takaneda I, Sato C, Sakamoto H. P53 and HER-2 alterations in renal cell carcinoma. Urology 1997; 50: 636–42.
   PubMed Web of Science ®Google Scholar
• Imai Y, Strohmeyer TG, Fleischhacker M, Slamon DJ, Koeffler HP. p53 mutations and MDM-2 amplification in renal cell cancers. Mod Pathol 1994; 7: 766–70.
   Google Scholar
• Foster K, Crossey PA, Cairns P, Hetherington JW, Richards FM, Jones MH, et al. Molecular genetic investigation of sporadic renal cell carcinoma: analysis of allele loss on chromosomes 3p, 5q, 11p, 17 and 22. Br J Cancer 1994; 69: 230–4.
   PubMed Web of Science ®Google Scholar
• Shiina H, Igawa M, Urakami S, Shirakawa H, Ishibe T, Kawanishi M. Clinical significance of immunohisto-chemically detectable p53 protein in renal cell carcino-ma. Eur Urol 1997; 31: 3–80.
   Google Scholar
• Van Velthoven R, Petein M, Oosterlink WJ, Zandona C, Zlotta A, Van der Meijden AP, et al. Image cytometrydetermination of ploidy level, proliferative activity, and nuclear size in a series of 314 transitional bladder carcinomas. Hum Pathol 1995; 26: 3–11.
   Google Scholar
• Contractor H, Zariwala M, Bugert P, Zeisler J, Kovacs G. Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour. J Pathol 1997; 181: 136–9.
   Google Scholar
• Dijkhuizen T, Van den Berg E, Van den Berg A, Storkel S, De Jong B, Seitz G, Henn W. Chromosomal findings and p53-mutation analysis in chromophilic renal-cell carcinomas. J Cancer 1996; 68: 47–50.
   Web of Science ®Google Scholar
• Hughson MD, Johnson LD, Silva FG, Kovacs G. Nonpapillary and papillary renal cell carcinoma: a cytogenetic and phenotypic study. Mod Pathol 1993; 6: 449–56.
   PubMed Web of Science ®Google Scholar